Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome

Biswanath Basu, Stella Preussler, Anja Sander, T K S Mahapatra, Franz Schaefer, Biswanath Basu, Stella Preussler, Anja Sander, T K S Mahapatra, Franz Schaefer

Abstract

Background: Approximately 30% of children with idiopathic nephrotic syndrome develop a complicated course with frequent relapses or steroid dependency. Rituximab, a B cell depleting monoclonal antibody, is a safe and effective alternative to steroids or other immunosuppressants for achieving and maintaining remission in this population at short term. Despite the good initial response relapses inevitably occur after regeneration of B lymphocytes, necessitating either repeat courses of rituximab or addition of another steroid-sparing immunosuppressant.

Methods: This is a prospective, single-center, open-label, two-parallel-arm randomized controlled phase III study among children with steroid dependent nephrotic syndrome who are maintained in remission with oral steroids. One hundred children will be randomized to either Rituximab and maintenance Mycophenolate mofetil (A) or repeated courses of prophylactic Rituximab only (B). In arm A, mycophenolate mofetil (1200 mg/m2 per day) will be started 3 months after Rituximab administration. In arm B, Rituximab infusions will be administered at 0, 8 and 16 months if B cell count normalize at the given time points. Prednisolone will be discontinued in both groups 2 weeks following first course of rituximab. Primary aim is to evaluate the difference in 24-month relapse-free survival. Main secondary endpoints are cumulative prednisolone dose, frequency of relapses and changes in anthropometry. Circulating B lymphocyte populations will be studied as biomarkers or predictors of rituximab responsiveness and adverse events will be analysed.

Discussion: The study will provide evidence as to the comparative safety and efficacy of two alternative steroid-sparing therapeutic options in children suffering from steroid dependent nephrotic syndrome. The two-year study design will address the long-term results obtained with the alternative treatment protocols.

Trial registration: This trial was prospectively registered to the Clinicaltrial.gov ( NCT03899103 dated 02/04/2019; https://clinicaltrials.gov/ ) and Clinical Trials Registry of India ( CTRI/2019/04/018517 dated 09/04/2019).

Keywords: Childhood nephrotic syndrome; Mycophenolate-Mofetil; Rituximab; Steroid dependent nephrotic syndrome.

Conflict of interest statement

The authors declare that they have no competing interests for the overall trial and the study site.

Figures

Fig. 1
Fig. 1
Study flow chart

References

    1. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2015, Issue Issue 3. Art. No.: CD001533. Art. No.: CD001533. DOI: 10.1002/14651858.CD001533.pub5.).
    1. Robinson RF, Nahata MC, Mahan JD, Batisky DL. Management of nephrotic syndrome in children. Pharmacotherapy. 2003;23:1021–1036. doi: 10.1592/phco.23.8.1021.32885.
    1. Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD002290. DOI: 10.1002/14651858.CD002290.pub5.
    1. Neuhaus TJ, Fay J, Dillon MJ, Trompeter RS, Barratt TM. Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome. Arch Dis Child. 1994;71:522–526. doi: 10.1136/adc.71.6.522.
    1. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:163–171. doi: 10.1038/kisup.2012.16.
    1. Abeyagunawardena AS, Dillon MJ, Rees L, Hoff W, van’t Trompeter RS. The use of steroid sparing agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2003;18:919–924. doi: 10.1007/s00467-003-1216-z.
    1. Basu B, Sander A, Roy B, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172(8):757–764. doi: 10.1001/jamapediatrics.2018.1323.
    1. Prytuła A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461–468. doi: 10.1007/s00467-009-1376-6.
    1. Kemper MJ, Gellermann J, Habbig S, et al. Long-term follow-up after rituximab for steroid dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910–1915. doi: 10.1093/ndt/gfr548.
    1. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomised controlled trial. Clin J Am Soc Nephrol. 2011;6:1308–1315. doi: 10.2215/CJN.09421010.
    1. Ravani P, Ponticelli A, Sicialiano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013;84:1025–1033. doi: 10.1038/ki.2013.211.
    1. Basu B, Mahapatra TK, Mondal N. Mycophenolate Mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics. 2015;136(1):e132–e139. doi: 10.1542/peds.2015-0486.
    1. Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26(10):1823–1828. doi: 10.1007/s00467-011-1886-x.
    1. Basu B, Schaefer F. Rituximab and MMF maintenance therapy in children with steroid dependent nephrotic syndrome: RITURNS trial follow-up. Abstract, ASN Kidney Week, 2019.
    1. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 ().
    1. International Conference on Harmonization (2019), “Final ICH E9 (R1) Addendum on ‘Estimands and Sensitivity Analysis in Clinical Trials’ to the Guideline on Statistical Principles for Clinical trials”.
    1. Sharma AP, Filler G. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Pediatr Nephrol. 2009;24(2):423–424. doi: 10.1007/s00467-008-1030-8.
    1. Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y. Shimizu T positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2015;30:687–691. doi: 10.1007/s00467-014-3034-x.
    1. Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109–1115. doi: 10.1007/s00467-010-1465-6.
    1. Kimata T, Hasui M, Kino J, et al. Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Nephrol. 2013;38:483–488. doi: 10.1159/000356439.
    1. Pendergraft WF, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. CJASN. 2014;9(4):736–744. doi: 10.2215/CJN.07340713.
    1. Cortazar FB, Rosenthal J, Laliberte K, Niles JL. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome. Clin Kidney J. 2018;12(2):224–231. doi: 10.1093/ckj/sfy067.
    1. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68(1):316–319. doi: 10.1093/biomet/68.1.316.
    1. ADDPLAN. Adaptive Designs – Plans and Analyses. Version 6.1.1. 2014; (last access Nov 29 2018).
    1. Kalbfleisch, J. D., & Ross, L. (1980). Prentice. The statistical analysis of failure time data, 2.
    1. Ravani P, et al. Rituximab in Children with Steroid- Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial [J]. JASN 2015, pii: ASN.2014080799(9):2259.
    1. Iijima K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial [J] Lancet. 2014;384(9950):1273–1281. doi: 10.1016/S0140-6736(14)60541-9.
    1. Kamei K, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017;32(11):2071–2078. doi: 10.1007/s00467-017-3718-0.
    1. Chan EY, Webb H, Yu E, Ghiggeri GM, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2020;97:393–401. doi: 10.1016/j.kint.2019.09.033.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner